Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Biotech
Despite ph. 3 miss, Alkeus sees path forward for eye disease med
Despite a phase 3 miss, Alkeus still sees a path forward for its oral eye disease asset.
Gabrielle Masson
Sep 17, 2024 10:58am
Merck has clear vision to eye disease assets with $3B EyeBio buy
May 29, 2024 8:32am
Innovent's Tepezza rival closer to China nod after phase 3 win
Feb 20, 2024 8:38am
iuvo BioScience acquires ophthalmology CRO Promedica
Jan 24, 2024 9:49am
Atsena downsizes to funnel money toward new capsid program
Oct 5, 2023 1:47pm
Astellas to test out 4DMT's eye disease gene therapy vector
Jul 10, 2023 7:30pm
